Ultragenyx Pharma (RARE) Misses Q3 EPS by 16c

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.03), $0.16 worse than the analyst estimate of ($0.87).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• RBC Capital Starts Ultragenyx Pharma (RARE) at Outperform 'Given Base Business Offers Downside Protection & OI Material Upside Potential'
• Eastgroup Properties (EGP) Tops Q1 EPS by 17c, provides guidance
• KKR Real Estate Finance Trust (KREF) Tops Q1 EPS by 4c